PER 5.26% 8.0¢ percheron therapeutics limited

Ann: Positive new DMD Combination Therapy Data in mdx mice, page-9

  1. 4,343 Posts.
    lightbulb Created with Sketch. 2023
    Be careful what you wish for. Their drug has yet to show the FDA that it really works. It was been restricted to a very small cohort, and only from a young age. This data tends to show they need ATL1102 to treat fibrous for their drug to show promise. ATL1102 still shows improvement as a mono therapy.

    We dont want to be undervalued. If the trial now running just replicates the previous trial serepta will be forgotten about (thats a bit tongue in cheek).

    Finance wise if those options come into the money this trial should be close to covered. Platinum have a large chunk of the company now, and will be seeing blood in the water.

    Drug can be approved for sale before EMA and FDA approvals are fully given, if certain criteria are met. And rare pediatric disease is a major criteria.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.004(5.26%)
Mkt cap ! $72.12M
Open High Low Value Volume
7.9¢ 8.0¢ 7.7¢ $35.48K 451.2K

Buyers (Bids)

No. Vol. Price($)
1 12500 7.8¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 198147 2
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.